Jing Ji Guan Cha Wang·2026-02-14 12:25Core Insights - The company has achieved significant global growth over the past year, marking a critical turning point towards profitability with its core self-developed BTK inhibitor, Baiyueze, establishing a leading position globally [1] - The company has launched its second self-developed product in the hematology field, the BCL2 inhibitor Baiyueda (Sotuximab), which is now commercially available [1] - The company has expanded its global footprint, with products available in over 75 markets and more than 2 million patients receiving treatment worldwide [1] Global Expansion and Market Impact - In Thailand, the approval process for Baizean took only 7 months, significantly reducing the time for patients to access innovative treatments [2] - In India, two self-developed products have benefited over 1,500 patients with positive clinical feedback [2] - The company is supporting the first immunotherapy clinical trial in sub-Saharan Africa through the provision of PD-1 inhibitors [2] - The Guangzhou production base not only serves domestic patients but also extends to markets in Indonesia, India, and South Korea, continuously expanding the company's global reach [2] Commitment to Innovation and Accessibility - The company aims to enhance drug accessibility in more countries and regions while continuing to expand its pipeline with a focus on scientific innovation [3] - The commitment to making innovative treatments available to more patients globally is seen as a long-term investment and a driving force for the company [3] Milestone Year - The year 2025 is highlighted as a milestone for the company, marking its 15th anniversary and a clearer, more determined new starting point in its globalization journey [4] Collaboration and Knowledge Sharing - The company emphasizes the importance of collaboration with various industry stakeholders to gather diverse experiences and insights, aiming to illuminate hope for more patients through scientific exploration [5]